Vaccine Pioneer Sees mRNA Technology's Limits in Treating Cancer – Bloomberg

Bloomberg Markets Americas. Live from New York, is focused on bringing you the most important global business and breaking markets news and information as it happens.
Bloomberg Markets live from New York, focused on bringing you the most important global business and breaking markets news and information as it happens.
Follow Bloomberg reporters as they uncover some of the biggest financial crimes of the modern era. This documentary-style series follows investigative journalists as they uncover the truth
Billions of Dollars in Fed Discount Window Suggests All Is Not Well in Banking
US Homebuilder Sentiment Extends Record Decline to 12 Months
UK’s Next Budget Will Take Place on March 15, Jeremy Hunt Says
Highest Interest Rates in 15 Years Are Derailing the American Dream
ECB’s Guindos Says Rate Hikes to Persist at ‘Similar Pace’
Where Things Stand Now With Inflation and the Fed
Health Experts Are Split on Who Should Get Covid Booster Shots and When 
Tesla Stock Rallies on Prospect of Elon Musk Stepping Back From Twitter
What Led Twitter Users Into Voting Elon Musk Out: Timeline
Apple Suppliers Accelerate Buildup Outside China, Analysts Say
London City Airport Waters Down Proposals for 40% Capacity Hike
YouTube Removed More Than 10,000 Videos Related to Midterms
‘Lord of the Rings’ Backer Starts Family Office With Goldman Hire
With Inflation Past Peak, KKR’s McVey Says It’s Time to Add Risk
The 13 Best Beers We Drank This Year
At 50, ‘Immaculate Reception’ Still Lifts a Region’s Spirits
When Housing Is for Locals Only, the Whole Country Suffers
Yet Again, America Isn’t Ready for a Recession
Now There’s Strep Throat for Parents to Worry About, Too
The Future of Work Is Lunch
Hollywood Loves Its Never-Ending Blizzard of Cheap Christmas Movies
Seven Takeaways From Businessweek’s Cocaine-Smuggling Cover Story
Employers Are Deflating Salaries in Job Listings to Keep Pay Down
Tesla Illegally Fired Workers for Criticizing Musk, Complaints Claim
Biden Rule Proposes Phasing Out Compact Flourescent Light Bulbs
Cabs Without a Chatty — Or Any — Driver Are Expanding in China
The (Slowly) Changing Face of Europe’s Mayors
Tech’s Bust Delivers Bruising Blow to Hollowed-Out San Francisco
Young Taiwanese Breathe New Life Into Villages Once Home to War Vets
Jane Street Culture: A View Into SBF’s Roots (Podcast)
Crypto.com’s World Cup Win Is Overshadowed by FTX Industry Chaos
Binance, Alone at the Top After FTX, Stirs ‘Too Big to Fail’ Crypto Worry
Naomi Kresge and
Veronika Gulyas
Subscriber Benefit
Subscribe
Sign In
One of the pioneers in messenger RNA vaccines sees limits to their effectiveness against cancers, even after a successful trial raised expectations for the technology. 
Tumor-fighting mRNA vaccines will probably be most useful for patients with only a few cancer cells, said Katalin Kariko, a former BioNTech SE executive and University of Pennsylvania researcher whose work helped lay the foundation for the technology’s success in the Covid-19 pandemic. 

source